Literature DB >> 20113982

Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low?

Chris T Bauch1, Meng Li, Gretchen Chapman, Alison P Galvani.   

Abstract

Human papillomavirus vaccine prevents infection by two major oncogenic types of the virus. Continued screening is needed in vaccinated women to prevent cancers caused by high-risk types not included in the vaccine. An exaggerated sense of protection from the vaccine could lead to a decline in the rate of screening among vaccinated women, which in principle could lead to an increase in the incidence of cervical cancer. We present a simple mathematical model of vaccination, screening, and disease incidence, including an analysis of the effect of data uncertainties. For a population with opportunistic screening and 30% vaccine coverage, screening rates in vaccinated women would have to decline by at least 80% (median value of probabilistic uncertainty analysis) before the incidence of cervical cancer would increase in the era since the introduction of the vaccine. By comparison, the decline needed is at least 49% in a population with organised screening and 70% vaccine coverage. In populations that have highly effective cervical screening programmes, incidence of cervical cancer starts to increase after smaller, but still substantial, decreases in screening. Introduction of vaccine is unlikely to lead to an increased incidence of cervical cancer as a result of diminished screening. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20113982     DOI: 10.1016/S1473-3099(10)70004-9

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  6 in total

1.  Cervical cytology screening among low-income, minority adolescents in New York City following the 2009 ACOG guidelines.

Authors:  Jennifer Tsui; Annika M Hofstetter; Karen Soren
Journal:  Prev Med       Date:  2014-03-17       Impact factor: 4.018

2.  Cervical cancer incidence in young women: a historical and geographic controlled UK regional population study.

Authors:  A Patel; K Galaal; C Burnley; K Faulkner; P Martin-Hirsch; M J Bland; S Leeson; H Beer; S Paranjothy; P Sasieni; R Naik
Journal:  Br J Cancer       Date:  2012-04-24       Impact factor: 7.640

3.  The ethics of implementing human papillomavirus vaccination in developed countries.

Authors:  Erik Malmqvist; Gert Helgesson; Johannes Lehtinen; Kari Natunen; Matti Lehtinen
Journal:  Med Health Care Philos       Date:  2011-02

4.  Barriers to and facilitators of compliance with clinic-based cervical cancer screening: population-based cohort study of women aged 23-60 years.

Authors:  Ellinor Östensson; Susanna Alder; K Miriam Elfström; Karin Sundström; Niklas Zethraeus; Marc Arbyn; Sonia Andersson
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

Review 5.  The Possible Effects on Socio-Economic Inequalities of Introducing HPV Testing as Primary Test in Cervical Cancer Screening Programs.

Authors:  Paolo Giorgi Rossi; Flavia Baldacchini; Guglielmo Ronco
Journal:  Front Oncol       Date:  2014-02-10       Impact factor: 6.244

6.  Intent to participate in future cervical cancer screenings is lower when satisfaction with the decision to be vaccinated is neutral.

Authors:  Natalie Marya Alexander; Diane Medved Harper; Johanna Claire Comes; Melissa Smith Smith; Melinda Ann Heutinck; Sandra Martin Handley; Debra Ann Ahern
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.